icon-folder.gif   Conference Reports for NATAP  
 
  ID Week
Oct 19, -23 2022
Washington DC

Back grey_arrow_rt.gif
 
 
A Real-World Observational Study on Patients With HIV Who Switched From Nevirapine + 2 Nucleoside Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada
 
 
  IDWeek 2022; October 19-23, 2022; Virtual and Washington, DC
 
Joseph J. de Wet,1,2 Joann K. Ban,3 Gustavo Verdier,4 Juejing Ling,5 Maria Eberg,5 Andrean Bunko,5 Michael McKimm4 1Spectrum Health, Vancouver, British Columbia, Canada; 2Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada; 3GSK, Mississauga, Ontario, Canada; 4ViiV Healthcare, Montréal, Québec, Canada; 5IQVIA, Kirkland, Québec, Canada

1023221

1023222

1023223

1023224

1023225

1023226

1023227